$XCUR
Exicure Inc Stock $xcur

$xcur Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000169853024000051 Filed on June 06, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.498M	$12.65M
YoY Change	-28.9%	16.19%
% of Gross Profit
Research & Development	$0.00	$1.423M
YoY Change	-100.0%	-92.8%
% of Gross Profit
Depreciation & Amortization	$7.000K	$634.0K
YoY Change	-97.51%	-45.49%
% of Gross Profit
Operating Expenses	$1.498M	$15.00M
YoY Change	-52.89%	-51.08%
Operating Profit		-$15.00M
YoY Change		719.01%
Interest Expense	$11.00K	$0.00
YoY Change	-59.26%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.918M
YoY Change	-100.0%	253.87%
Pretax Income	-$1.487M	-$16.91M
YoY Change	-107.99%	612.77%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.487M	-$16.91M
YoY Change	-108.08%	555.07%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.11
Diluted Earnings Per Share	-$0.17	-$2.11
COMMON SHARES
Basic Shares Outstanding		8.014M shares
Diluted Shares Outstanding		8.014M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$816.0K	$816.0K
YoY Change	-90.49%	-90.49%
Cash & Equivalents	$816.0K	$816.0K
Short-Term Investments
Other Short-Term Assets	$1.193M	$1.193M
YoY Change	-19.06%	-19.06%
Inventory
Prepaid Expenses	$0.00
Receivables
Other Receivables
Total Short-Term Assets	$2.024M	$2.024M
YoY Change	-79.86%	-79.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$54.00K	$6.571M
YoY Change	-97.87%	-32.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.985M	$2.985M
YoY Change	-14.47%	-14.47%
Total Long-Term Assets	$9.556M	$9.556M
YoY Change	-28.03%	-28.03%
TOTAL ASSETS
Total Short-Term Assets	$2.024M	$2.024M
Total Long-Term Assets	$9.556M	$9.556M
Total Assets	$11.58M	$11.58M
YoY Change	-50.36%	-50.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.631M	$1.631M
YoY Change	351.8%	351.8%
Accrued Expenses	$879.0K	$879.0K
YoY Change	-31.22%	-31.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$2.510M	$2.510M
YoY Change	53.14%	53.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.039M	$6.039M
YoY Change		-10.76%
Total Long-Term Liabilities	$6.039M	$6.039M
YoY Change		-10.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.510M	$2.510M
Total Long-Term Liabilities	$6.039M	$6.039M
Total Liabilities	$8.549M	$8.549M
YoY Change	1.7%	1.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$189.6M
YoY Change	9.8%
Common Stock	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.031M	$3.031M
YoY Change
Total Liabilities & Shareholders Equity	$11.58M	$11.58M
YoY Change	-50.36%	-50.36%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.487M	-$16.91M
YoY Change	-108.08%	555.07%
Depreciation, Depletion And Amortization	$7.000K	$634.0K
YoY Change	-97.51%	-45.49%
Cash From Operating Activities	-$816.0K	-$10.36M
YoY Change	-88.79%	-70.95%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$711.0K	-$1.078M
YoY Change	243.48%	-122.91%
Cash From Investing Activities	$711.0K	-$1.078M
YoY Change	243.48%	-122.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$5.440M
YoY Change		7.94%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	-1.000K	$3.674M
YoY Change		-218.33%
NET CHANGE
Cash From Operating Activities	-816.0K	-$10.36M
Cash From Investing Activities	711.0K	-$1.078M
Cash From Financing Activities	-1.000K	$3.674M
Net Change In Cash	-106.0K	-$7.761M
YoY Change	-98.5%	-77.22%
FREE CASH FLOW
Cash From Operating Activities	-$816.0K	-$10.36M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$816.0K	-$10.36M
YoY Change	-88.79%	-70.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5800000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8651148	shares
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Chicago, IL
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	879000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1639000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4965901	shares
CY2023	us-gaap	Investment Income Dividend InvestmentIncomeDividend	52000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1831000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1918000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16914000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16914000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16914000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-122000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	39000	usd
CY2023	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-40000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-542000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11232000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14996000	usd
CY2022	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	14996000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001698530
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39011
CY2023	dei	Entity Registrant Name EntityRegistrantName	EXICURE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-5333008
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2430 N. Halsted St.
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Chicago
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60614
CY2023	dei	City Area Code CityAreaCode	847
CY2023	dei	Local Phone Number LocalPhoneNumber	673-1700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	XCUR
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Chicago, IL
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	816000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8577000	usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	15000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34067000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43844000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2016000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	816000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8577000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. These reclassifications had no effect on the previously reported operating results.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	816000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1193000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1474000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2024000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10051000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2530000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6517000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7257000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2985000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3490000	usd
CY2023Q4	us-gaap	Assets Assets	11580000	usd
CY2022Q4	us-gaap	Assets Assets	23328000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1631000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	361000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1278000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2510000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6039000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6767000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8549000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8406000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8650753	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8650753	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4965901	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192593000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187571000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189563000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172649000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3031000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14922000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11580000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23328000	usd
CY2023	xcur	Revenue From Contract With Customer Net Of Cumulative Catch Up Adjustment RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment	0	usd
CY2022	xcur	Revenue From Contract With Customer Net Of Cumulative Catch Up Adjustment RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment	28826000	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	28826000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1423000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19767000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12653000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10890000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	14996000	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2022	us-gaap	Investment Income Dividend InvestmentIncomeDividend	78000	usd
CY2022	us-gaap	Interest Expense InterestExpense	595000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2373000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2582000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8013840	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8013840	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4619471	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4619471	shares
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2580000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1369000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-4000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4900000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2582000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14922000	usd
CY2023	xcur	Adjustments To Additional Paid In Capital Decrease Related To Reclassification AdjustmentsToAdditionalPaidInCapitalDecreaseRelatedToReclassification	800000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1348000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4597000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16914000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3031000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16914000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2582000	usd
CY2023	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	634000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1163000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	741000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	693000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1348000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1369000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	477000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2022	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-920000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-733000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3051000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-38000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2165000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1270000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3052000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-399000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5186000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-28826000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-728000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-637000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10357000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35658000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2000000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1499000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	6000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	922000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	205000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1078000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4696000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5440000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5040000	usd
CY2023	xcur	Payments Of Common Stock Financing Costs PaymentsOfCommonStockFinancingCosts	843000	usd
CY2022	xcur	Payments Of Common Stock Financing Costs PaymentsOfCommonStockFinancingCosts	154000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7500000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14000	usd
CY2023	xcur	Payment For Exercise Of Common Stock Warrant PaymentForExerciseOfCommonStockWarrant	800000	usd
CY2022	xcur	Payment For Exercise Of Common Stock Warrant PaymentForExerciseOfCommonStockWarrant	0	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	123000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3674000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-733000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3051000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-38000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2165000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3052000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-399000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5186000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-28826000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-728000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-637000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10357000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35658000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2000000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1499000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	6000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	922000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1078000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4696000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5040000	usd
CY2023	xcur	Payments Of Common Stock Financing Costs PaymentsOfCommonStockFinancingCosts	843000	usd
CY2022	xcur	Payments Of Common Stock Financing Costs PaymentsOfCommonStockFinancingCosts	154000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	506000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7500000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14000	usd
CY2023	xcur	Payment For Exercise Of Common Stock Warrant PaymentForExerciseOfCommonStockWarrant	800000	usd
CY2022	xcur	Payment For Exercise Of Common Stock Warrant PaymentForExerciseOfCommonStockWarrant	0	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	123000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3674000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3105000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7761000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34067000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43844000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2016000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8577000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1193000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1474000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8611000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1946000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3105000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34067000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	816000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8577000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9777000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. These reclassifications had no effect on the previously reported operating results.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.
CY2023Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1200000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6665000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. These reclassifications had no effect on the previously reported operating results.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.
CY2023Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1200000	usd
CY2023Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1200000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	usd
CY2023Q4	xcur	Debt Securities Available For Sale Principal Amount DebtSecuritiesAvailableForSalePrincipalAmount	2000000	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and other risks and uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. The Company places its cash, cash equivalents, and short-term investments with reputable financial institutions. The Company primarily invests its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company has not experienced any credit losses in such accounts. The Company has no financial instruments with off-balance sheet risk of loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company’s revenue was generated from its collaborations with Ipsen and AbbVie, which were terminated in the fourth quarter of 2022 resulting in no revenue for 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company’s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks associated with its exploration of strategic alternatives including, but not limited, the inability to identify any transactions that will generate value for stockholders, incurrence of excessive costs in seeking to identify and pursue transactions and the possibility that any transaction the Company does pursue will not provide anticipated benefits.</span></div>
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	usd
CY2023Q4	xcur	Debt Securities Available For Sale Principal Amount DebtSecuritiesAvailableForSalePrincipalAmount	2000000	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and other risks and uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. The Company places its cash, cash equivalents, and short-term investments with reputable financial institutions. The Company primarily invests its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company has not experienced any credit losses in such accounts. The Company has no financial instruments with off-balance sheet risk of loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company’s revenue was generated from its collaborations with Ipsen and AbbVie, which were terminated in the fourth quarter of 2022 resulting in no revenue for 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company’s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks associated with its exploration of strategic alternatives including, but not limited, the inability to identify any transactions that will generate value for stockholders, incurrence of excessive costs in seeking to identify and pursue transactions and the possibility that any transaction the Company does pursue will not provide anticipated benefits.</span></div>
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	usd
CY2023Q4	xcur	Debt Securities Available For Sale Principal Amount DebtSecuritiesAvailableForSalePrincipalAmount	2000000	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	408000	usd
CY2023Q4	xcur	Prepaid Franchise Tax PrepaidFranchiseTax	259000	usd
CY2022Q4	xcur	Prepaid Franchise Tax PrepaidFranchiseTax	223000	usd
CY2023Q4	xcur	Lease Cost Current LeaseCostCurrent	235000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	xcur	Lease Cost Current LeaseCostCurrent	111000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	191000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	519000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1193000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1474000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	191000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	519000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	408000	usd
CY2023Q4	xcur	Prepaid Franchise Tax PrepaidFranchiseTax	259000	usd
CY2022Q4	xcur	Prepaid Franchise Tax PrepaidFranchiseTax	223000	usd
CY2023Q4	xcur	Lease Cost Current LeaseCostCurrent	235000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	213000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	508000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	408000	usd
CY2023Q4	xcur	Prepaid Franchise Tax PrepaidFranchiseTax	259000	usd
CY2022Q4	xcur	Prepaid Franchise Tax PrepaidFranchiseTax	223000	usd
CY2023Q4	xcur	Lease Cost Current LeaseCostCurrent	235000	usd
CY2022Q4	xcur	Lease Cost Current LeaseCostCurrent	111000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	191000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	519000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1193000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1474000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2023Q4	xcur	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	1785000	usd
CY2022Q4	xcur	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	2252000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	0	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	38000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2023Q4	xcur	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	1785000	usd
CY2022Q4	xcur	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	2252000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	0	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	38000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2985000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3490000	usd
CY2022Q4	xcur	Accrued Clinical Contract Research And Manufacturing Costs Current AccruedClinicalContractResearchAndManufacturingCostsCurrent	48000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	48000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	626000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	539000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	71000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	182000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	611000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	879000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1278000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1271000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1310000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1349000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1390000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2158000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2023Q4	xcur	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	1785000	usd
CY2022Q4	xcur	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	2252000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	0	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	38000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2985000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3490000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	279000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6180000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	225000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3650000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2530000	usd
CY2023	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	634000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1163000	usd
CY2023Q4	xcur	Accrued Clinical Contract Research And Manufacturing Costs Current AccruedClinicalContractResearchAndManufacturingCostsCurrent	0	usd
CY2022Q4	xcur	Accrued Clinical Contract Research And Manufacturing Costs Current AccruedClinicalContractResearchAndManufacturingCostsCurrent	48000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	48000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	626000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	539000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	71000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	182000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	611000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1278000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	279000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6180000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	225000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3650000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2530000	usd
CY2023	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	634000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1163000	usd
CY2023Q4	xcur	Accrued Clinical Contract Research And Manufacturing Costs Current AccruedClinicalContractResearchAndManufacturingCostsCurrent	0	usd
CY2022Q4	xcur	Accrued Clinical Contract Research And Manufacturing Costs Current AccruedClinicalContractResearchAndManufacturingCostsCurrent	48000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	48000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	626000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	539000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	182000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	611000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	879000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1278000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2020Q3	xcur	Debt Instrument Exit Fee Percentage DebtInstrumentExitFeePercentage	0.0375
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1390000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2158000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8611000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1946000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6665000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2020Q3	xcur	Debt Instrument Exit Fee Percentage DebtInstrumentExitFeePercentage	0.0375
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1305000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	690000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1529000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1479000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2851000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1808000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3024000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1133000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1349000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2020Q3	xcur	Debt Instrument Exit Fee Percentage DebtInstrumentExitFeePercentage	0.0375
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	789000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1305000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	690000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1529000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1479000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2851000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1808000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3024000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1133000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	789000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	690000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1529000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1479000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2851000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1808000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3024000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1133000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1271000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1310000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1349000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1390000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2158000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8611000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1946000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6665000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	626000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6039000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6665000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	550000	usd
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	1191000	usd
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	1643000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	488000	usd
CY2022	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	12000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1348000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1348000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1369000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	619000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	626000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6039000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6665000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	550000	usd
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	1191000	usd
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	1643000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	488000	usd
CY2022	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	12000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8650753	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8650753	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4965901	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4965901	shares
CY2023Q4	xcur	Common Stock Voting Rightsfor Each Share CommonStockVotingRightsforEachShare	1	vote
CY2022Q3	xcur	Registration Rights Agreement Required Filing Term RegistrationRightsAgreementRequiredFilingTerm	P90D
CY2022Q3	xcur	Registration Rights Agreement Liquidation Damages Payable As A Percent Of Amount Invested If Filed Late RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate	0.005
CY2022Q3	xcur	Registration Rights Agreement Liquidation Damages Payable If Filed Late Measurement Term RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm	P30D
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	xcur	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	11478000	usd
CY2021Q4	xcur	Proceeds From Issuance Of Common Stock And Warrants Net Of Placement Agent Fee And Other Offering Expenses Payable ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable	10226000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation ClassOfWarrantOrRightOwnershipPercentageLimitation	0.0499
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation At Election Of Purchaser ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser	0.0999
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation ClassOfWarrantOrRightOwnershipPercentageLimitation	0.0499
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation At Election Of Purchaser ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser	0.0999
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	576261	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.1031
CY2023Q2	xcur	Class Of Warrant Or Right Payment For Liability ClassOfWarrantOrRightPaymentForLiability	800000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	626000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6039000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6665000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	550000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	1191000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	488000	usd
CY2022	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	12000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8650753	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4965901	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4965901	shares
CY2023Q4	xcur	Common Stock Voting Rightsfor Each Share CommonStockVotingRightsforEachShare	1	vote
CY2022Q3	xcur	Registration Rights Agreement Required Filing Term RegistrationRightsAgreementRequiredFilingTerm	P90D
CY2022Q3	xcur	Registration Rights Agreement Liquidation Damages Payable As A Percent Of Amount Invested If Filed Late RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate	0.005
CY2022Q3	xcur	Registration Rights Agreement Liquidation Damages Payable If Filed Late Measurement Term RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm	P30D
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	xcur	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	11478000	usd
CY2021Q4	xcur	Proceeds From Issuance Of Common Stock And Warrants Net Of Placement Agent Fee And Other Offering Expenses Payable ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable	10226000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation ClassOfWarrantOrRightOwnershipPercentageLimitation	0.0499
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation At Election Of Purchaser ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser	0.0999
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation ClassOfWarrantOrRightOwnershipPercentageLimitation	0.0499
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation At Election Of Purchaser ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser	0.0999
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	576261	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.1031
CY2023Q2	xcur	Class Of Warrant Or Right Payment For Liability ClassOfWarrantOrRightPaymentForLiability	800000	usd
CY2023Q2	xcur	Class Of Warrant Or Right Number Of Securities Settled In Period ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod	526151	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	50110	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.031
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	48000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	48000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8650753	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8650753	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4965901	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4965901	shares
CY2023Q4	xcur	Common Stock Voting Rightsfor Each Share CommonStockVotingRightsforEachShare	1	vote
CY2022Q3	xcur	Registration Rights Agreement Required Filing Term RegistrationRightsAgreementRequiredFilingTerm	P90D
CY2022Q3	xcur	Registration Rights Agreement Liquidation Damages Payable As A Percent Of Amount Invested If Filed Late RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate	0.005
CY2022Q3	xcur	Registration Rights Agreement Liquidation Damages Payable If Filed Late Measurement Term RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm	P30D
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	xcur	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	11478000	usd
CY2021Q4	xcur	Proceeds From Issuance Of Common Stock And Warrants Net Of Placement Agent Fee And Other Offering Expenses Payable ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable	10226000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation ClassOfWarrantOrRightOwnershipPercentageLimitation	0.0499
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation At Election Of Purchaser ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser	0.0999
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation ClassOfWarrantOrRightOwnershipPercentageLimitation	0.0499
CY2021Q4	xcur	Class Of Warrant Or Right Ownership Percentage Limitation At Election Of Purchaser ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser	0.0999
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	576261	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.1031
CY2023Q2	xcur	Class Of Warrant Or Right Payment For Liability ClassOfWarrantOrRightPaymentForLiability	800000	usd
CY2023Q2	xcur	Class Of Warrant Or Right Number Of Securities Settled In Period ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod	526151	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	50110	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.031
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1348000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1369000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	619000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	619000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0383
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0383
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0286
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0356
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.009
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.009
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.952
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.958
CY2023	xcur	Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate	0.05
CY2022	xcur	Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.52
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	331420	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232028	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.56
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	124	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.51
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	340491	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	60.18
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	222833	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.74
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.58
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	220718	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022Q2	xcur	Stock Option Exercise Price StockOptionExercisePrice	5.51
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0383
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0383
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0286
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0356
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.009
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.009
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.952
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.958
CY2023	xcur	Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate	0.05
CY2022	xcur	Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.52
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	331420	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	61.82
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232028	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	340491	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	60.18
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	222833	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	220718	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022Q2	xcur	Stock Option Exercise Price StockOptionExercisePrice	5.51
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0383
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0383
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0286
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0356
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.009
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.009
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.952
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.958
CY2023	xcur	Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate	0.05
CY2022	xcur	Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.52
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	331420	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	61.82
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232028	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.51
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	340491	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	60.18
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	222833	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.74
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.58
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	220718	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.40
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12115	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022Q2	xcur	Stock Option Exercise Price StockOptionExercisePrice	5.51
CY2022Q2	xcur	Stock Option Exercise Price StockOptionExercisePrice	5.51
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	233224	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16914000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2373000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	115000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	94000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022Q2	xcur	Stock Option Exercise Price StockOptionExercisePrice	5.51
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	233224	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16914000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2373000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	115000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	94000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	209000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16914000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2373000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	115000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	209000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3552000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-498000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3552000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-498000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1167000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.069
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-87000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	285000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.017
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	108000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.046
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	31000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.013
CY2023	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Amount EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRateAmount	72000	usd
CY2023	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent	-0.005
CY2022	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Amount EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRateAmount	-16000	usd
CY2022	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent	0.007
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-39891000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.369
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	733000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.309
CY2023	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Amount EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesAmount	44253000	usd
CY2023	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Percent EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesPercent	-2.626
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3145000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36331000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3552000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-498000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1167000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.069
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	285000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.017
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	108000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.046
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	31000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.013
CY2023	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Amount EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRateAmount	72000	usd
CY2023	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent	-0.005
CY2022	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent	0.007
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-39891000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.369
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	733000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.309
CY2023	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Amount EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesAmount	44253000	usd
CY2023	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Percent EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesPercent	-2.626
CY2022	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Amount EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesAmount	0	usd
CY2022	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Percent EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesPercent	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.088
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3145000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36331000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-87000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	285000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.046
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	31000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.013
CY2023	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Amount EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRateAmount	72000	usd
CY2023	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent	-0.005
CY2022	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Amount EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRateAmount	-16000	usd
CY2022	xcur	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent	0.007
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-39891000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.369
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	733000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.309
CY2023	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Amount EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesAmount	44253000	usd
CY2023	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Percent EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesPercent	-2.626
CY2022	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Amount EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesAmount	0	usd
CY2022	xcur	Effective Income Tax Rate Reconciliation Reduction Of Worthless Attributes Percent EffectiveIncomeTaxRateReconciliationReductionOfWorthlessAttributesPercent	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	209000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.088
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3145000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36331000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	472000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	741000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	41000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	40000	usd
CY2023Q4	xcur	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1900000	usd
CY2022Q4	xcur	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	2097000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1874000	usd
CY2023Q4	xcur	Deferred Tax Assets Investment Loss Adjustment DeferredTaxAssetsInvestmentLossAdjustment	570000	usd
CY2022Q4	xcur	Deferred Tax Assets Investment Loss Adjustment DeferredTaxAssetsInvestmentLossAdjustment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	56000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44145000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2147000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	472000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	741000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5795000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	117000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	41000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	40000	usd
CY2023Q4	xcur	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1900000	usd
CY2022Q4	xcur	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	2097000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1874000	usd
CY2023Q4	xcur	Deferred Tax Assets Investment Loss Adjustment DeferredTaxAssetsInvestmentLossAdjustment	570000	usd
CY2022Q4	xcur	Deferred Tax Assets Investment Loss Adjustment DeferredTaxAssetsInvestmentLossAdjustment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	56000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44145000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2147000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2637000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	217000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	262000	usd
CY2023Q4	xcur	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	15000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	292000	usd
CY2023Q4	xcur	Deferred Tax Liabilities Deferred Rent DeferredTaxLiabilitiesDeferredRent	57000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Deferred Rent DeferredTaxLiabilitiesDeferredRent	0	usd
CY2022Q4	xcur	Deferred Tax Liabilities Operating Lease Asset DeferredTaxLiabilitiesOperatingLeaseAsset	2083000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2147000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2637000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16914000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16914000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2582000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2582000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8013840	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8013840	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4619471	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4619471	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	472000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	741000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5795000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	117000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	41000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	40000	usd
CY2023Q4	xcur	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1900000	usd
CY2022Q4	xcur	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	2097000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1874000	usd
CY2023Q4	xcur	Deferred Tax Assets Investment Loss Adjustment DeferredTaxAssetsInvestmentLossAdjustment	570000	usd
CY2022Q4	xcur	Deferred Tax Assets Investment Loss Adjustment DeferredTaxAssetsInvestmentLossAdjustment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44145000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2147000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2637000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	217000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	262000	usd
CY2023Q4	xcur	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	15000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	292000	usd
CY2023Q4	xcur	Deferred Tax Liabilities Deferred Rent DeferredTaxLiabilitiesDeferredRent	57000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Deferred Rent DeferredTaxLiabilitiesDeferredRent	0	usd
CY2023Q4	xcur	Deferred Tax Liabilities Operating Lease Asset DeferredTaxLiabilitiesOperatingLeaseAsset	1858000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Operating Lease Asset DeferredTaxLiabilitiesOperatingLeaseAsset	2083000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2147000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2637000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16914000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16914000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2582000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2582000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8013840	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8013840	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4619471	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4619471	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2637000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	217000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	262000	usd
CY2023Q4	xcur	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	15000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	292000	usd
CY2023Q4	xcur	Deferred Tax Liabilities Deferred Rent DeferredTaxLiabilitiesDeferredRent	57000	usd
CY2022Q4	xcur	Deferred Tax Liabilities Deferred Rent DeferredTaxLiabilitiesDeferredRent	0	usd
CY2023Q4	xcur	Deferred Tax Liabilities Operating Lease Asset DeferredTaxLiabilitiesOperatingLeaseAsset	1858000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2147000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2637000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16914000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16914000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2582000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2582000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8013840	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8013840	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4619471	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4619471	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022Q4	xcur	Class Of Warrant Or Right Outstanding Fair Value Per Share ClassOfWarrantOrRightOutstandingFairValuePerShare	0
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023	xcur	Class Of Warrant Or Right Additions ClassOfWarrantOrRightAdditions	526000	shares
CY2023	xcur	Class Of Warrant Or Right Additions Fair Value Per Share ClassOfWarrantOrRightAdditionsFairValuePerShare	1.52
CY2023	xcur	Warrants And Rights Outstanding Additions WarrantsAndRightsOutstandingAdditions	800000	usd
CY2023	xcur	Class Of Warrant Or Right Payments ClassOfWarrantOrRightPayments	526000	shares
CY2023	xcur	Class Of Warrant Or Right Payments Fair Value Per Share ClassOfWarrantOrRightPaymentsFairValuePerShare	1.52
CY2023	xcur	Warrants And Rights Outstanding Payment WarrantsAndRightsOutstandingPayment	800000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2023Q4	xcur	Class Of Warrant Or Right Outstanding Fair Value Per Share ClassOfWarrantOrRightOutstandingFairValuePerShare	0
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023	xcur	Debt Securities Available For Sale Purchases DebtSecuritiesAvailableForSalePurchases	2000000	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022Q4	xcur	Class Of Warrant Or Right Outstanding Fair Value Per Share ClassOfWarrantOrRightOutstandingFairValuePerShare	0
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023	xcur	Class Of Warrant Or Right Additions ClassOfWarrantOrRightAdditions	526000	shares
CY2023	xcur	Class Of Warrant Or Right Additions Fair Value Per Share ClassOfWarrantOrRightAdditionsFairValuePerShare	1.52
CY2023	xcur	Warrants And Rights Outstanding Additions WarrantsAndRightsOutstandingAdditions	800000	usd
CY2023	xcur	Class Of Warrant Or Right Payments ClassOfWarrantOrRightPayments	526000	shares
CY2023	xcur	Class Of Warrant Or Right Payments Fair Value Per Share ClassOfWarrantOrRightPaymentsFairValuePerShare	1.52
CY2023	xcur	Warrants And Rights Outstanding Payment WarrantsAndRightsOutstandingPayment	800000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2023Q4	xcur	Class Of Warrant Or Right Outstanding Fair Value Per Share ClassOfWarrantOrRightOutstandingFairValuePerShare	0
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	119000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	276000	usd
CY2023	xcur	Paymentsfor License Agreements PaymentsforLicenseAgreements	11567000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022Q4	xcur	Class Of Warrant Or Right Outstanding Fair Value Per Share ClassOfWarrantOrRightOutstandingFairValuePerShare	0
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023	xcur	Class Of Warrant Or Right Additions ClassOfWarrantOrRightAdditions	526000	shares
CY2023	xcur	Class Of Warrant Or Right Additions Fair Value Per Share ClassOfWarrantOrRightAdditionsFairValuePerShare	1.52
CY2023	xcur	Class Of Warrant Or Right Payments ClassOfWarrantOrRightPayments	526000	shares
CY2023	xcur	Class Of Warrant Or Right Payments Fair Value Per Share ClassOfWarrantOrRightPaymentsFairValuePerShare	1.52
CY2023	xcur	Warrants And Rights Outstanding Payment WarrantsAndRightsOutstandingPayment	800000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2023Q4	xcur	Class Of Warrant Or Right Outstanding Fair Value Per Share ClassOfWarrantOrRightOutstandingFairValuePerShare	0
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023	xcur	Debt Securities Available For Sale Purchases DebtSecuritiesAvailableForSalePurchases	2000000	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023	xcur	Changes In Fair Value Of Investment In Convertible Notes Receivable ChangesInFairValueOfInvestmentInConvertibleNotesReceivable	2000000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	119000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	276000	usd
CY2023	xcur	Paymentsfor License Agreements PaymentsforLicenseAgreements	11567000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	119000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	276000	usd
CY2023	xcur	Paymentsfor License Agreements PaymentsforLicenseAgreements	11567000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
xcur-20231231_htm.xml	Edgar Link	completed
0001698530-24-000051-index-headers.html	Edgar Link	pending
0001698530-24-000051-index.html	Edgar Link	pending
0001698530-24-000051.txt	Edgar Link	pending
0001698530-24-000051-xbrl.zip	Edgar Link	pending
exicureexhibit231123123.htm	Edgar Link	pending
exicureexhibit232123123.htm	Edgar Link	pending
exicureexhibit311-123123.htm	Edgar Link	pending
exicureexhibit312-123123.htm	Edgar Link	pending
exicureexhibit321-123123.htm	Edgar Link	pending
exicureexhibit97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xcur-20231231.htm	Edgar Link	pending
xcur-20231231.xsd	Edgar Link	pending
xcur-20231231_cal.xml	Edgar Link	unprocessable
xcur-20231231_def.xml	Edgar Link	unprocessable
xcur-20231231_pre.xml	Edgar Link	unprocessable
xcur-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XCUR
Exicure Inc Stock $xcur

2023 Q4 Form 10-K Financial Statement

#000169853024000051 Filed on June 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XCUR Exicure Inc Stock $xcur

2023 Q4 Form 10-K Financial Statement

#000169853024000051 Filed on June 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XCUR
Exicure Inc Stock $xcur